Intracerebral Hemorrhage Medical Slides
Generate publication-quality intracerebral hemorrhage lecture slides in 30 seconds. AI-powered content structured for clinical education.
Generate Intracerebral Hemorrhage DeckWhy teach Intracerebral Hemorrhage?
Intracerebral hemorrhage accounts for 10-15% of all strokes but carries the highest mortality rate of any stroke subtype (40% at 30 days). Hematoma expansion in the first 6 hours is the primary modifiable prognostic factor. The INTERACT2, ATACH-2, and INTERACT3 trials have refined blood pressure targets, while the pivotal PATCH and INCH trials guide anticoagulant reversal decisions.
What AI generates for Intracerebral Hemorrhage
Enter “Intracerebral Hemorrhage” and SlideCraft generates a complete lecture deck with slides like these.
See it in action
Type any medical topic and watch AI generate a presentation slide in seconds. No signup required.
3 free previews per hour · No account needed
Enter a topic and click Generate to see your AI slide
Intracerebral Hemorrhage Presentation FAQ
How should ICH blood pressure management be presented in teaching?
Present the evolving evidence: INTERACT2 (2013) showed intensive lowering to <140 mmHg SBP was safe with trend toward functional benefit. ATACH-2 (2016) found no additional benefit with target <120 mmHg and increased renal adverse events. Current AHA/ASA recommendation: target SBP 130-150 mmHg within 2 hours for patients presenting with SBP 150-220 mmHg. INTERACT3 (2023) showed that a care bundle including rapid BP lowering improved functional outcomes.
What anticoagulant reversal protocols should be included?
Present reversal agents by anticoagulant: warfarin (4-factor PCC 25-50 IU/kg + IV vitamin K 10 mg, target INR <1.4), dabigatran (idarucizumab 5g IV, immediate complete reversal), rivaroxaban/apixaban (andexanet alfa or 4-factor PCC 50 IU/kg if andexanet unavailable). Emphasize the time-critical nature: reversal should be administered within 60 minutes of presentation. Reference the ANNEXA-4 trial for andexanet alfa and the RE-VERSE AD trial for idarucizumab.
How should surgical evacuation indications be taught for ICH?
Present the evidence hierarchy: STICH (2005) showed no benefit of early surgery for supratentorial ICH overall. STICH II (2013) found no benefit for superficial lobar ICH. MISTIE III (2019) showed that minimally invasive catheter-based evacuation to <15 mL residual improved functional outcomes but not mortality. Cerebellar hemorrhage >3 cm with brainstem compression remains a Class I surgical indication. Frame surgery as an evolving field with minimally invasive approaches showing the most promise.
Simple pricing, no surprises
Start free today. Upgrade when your department needs more.
Free
Try SlideCraft with no commitment
- 2 decks per month
- AI slides with speaker notes
- View & present only (no export)
- 7-day cloud storage
- Slide Checker & Outline Generator
Pro
For clinicians who lecture weekly
- 10 decks/mo + $2.50/extra
- AI Critic Mode (5-axis review)
- Document-to-deck (PDF upload)
- PDF, PPTX, SCORM & image export
- Permanent cloud storage
Expert
For academic physicians who publish and present
- 25 decks/mo + $2.00/extra
- PubMed source verification
- Paper-to-deck pipeline
- Auto-citations (Vancouver)
- Everything in Pro